Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025

Key Terms

cord blood bank medical

A cord blood bank stores the blood collected from a newborn’s umbilical cord and placenta because that blood contains versatile stem cells that can be used to treat certain diseases. Think of it as a biological savings account: parents or hospitals pay to preserve a potential medical resource, and the business model involves storage fees, clinical services and potential partnerships with therapy developers. For investors, demand, regulation, and advances in treatments drive revenue potential and risk.

stem cells medical

Stem cells are versatile biological “building blocks” that can develop into different kinds of specialized cells, such as blood, nerve, or muscle cells, and can also self-replicate. They matter to investors because they underpin research and potential treatments that could create new medicines, medical devices, or diagnostics, offering significant upside if successful while also carrying long development timelines, regulatory hurdles, and scientific risk.

public banking medical

A public bank is a financial institution owned and run by a government or public authority to serve community needs—accepting deposits, making loans, and managing public funds—rather than to maximize profits for private shareholders. Think of it like a city-owned utility for money: it can provide cheaper financing for local projects, stabilize credit during downturns, and steer lending toward public priorities, so investors watch it for impacts on local credit supply, competition with private banks, and potential shifts in regional economic risk.

fda registered regulatory

FDA registered means a company or facility has listed itself with the U.S. Food and Drug Administration and provided details about where and how certain products are made; it is a bookkeeping step that lets regulators know who is manufacturing or importing regulated items. It matters to investors because registration is a basic compliance signal—like a business license—indicating the company is on the regulator’s radar, but it is not the same as FDA approval or endorsement of product safety or effectiveness.

cgmp medical

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

aabb accredited medical

AABB accredited means a blood bank, transfusion service, cord blood bank or cellular therapy program has passed an independent quality and safety review by AABB (a standards-setting organization for blood products and related services). For investors, accreditation is like a safety and quality stamp that reduces operational and regulatory risk, supports customer and partner trust, and can influence a provider’s ability to win contracts, obtain licenses, or access certain markets.

fact accreditation medical

Fact accreditation is an independent verification that specific claims or figures in a corporate announcement are true and supported by evidence, similar to an inspector’s stamp on a safety report. For investors, it matters because accredited facts reduce the risk of relying on false or misleading information, helping to judge a company’s credibility and make more confident decisions about buying, holding, or selling securities.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025.

Financial Results

Revenue

Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue and $130,000 in public banking revenue compared to $31.6 million in processing and storage fee revenue, $68,000 in product revenue and $367,000 in public banking revenue for fiscal 2024.

Net (Loss) Income

The Company reported a net loss of $2.4 million in fiscal 2025 or $0.30 per basic and diluted share, compared to net income of $402,000 in fiscal 2024 or $0.05 per basic and diluted share. Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $4.4 million was recognized during the fourth quarter of November 30, 2025 to reduce the public inventory from cost to net realizable value.

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. ‎More than 500,000 parents from 87 countries have entrusted Cryo-Cell International, Inc. with ‎their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell ‎International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell’s ‎public bank has provided cord blood for more than 700 transplants and operates a cord ‎blood donation site at one of the country’s most prominent hospitals, Cedars–Sinai Hospital in ‎Los Angeles. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-‎compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization. Cryo-Cell has ‎the exclusive rights ‎to PrepaCyte-CB, the industry’s most advanced cord blood processing ‎technology.‎

Cryo-Cell’s mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-Q filed on October 15, 2025.

This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260227119036/en/

Irene Smith
813-749-2102
Ismith@cryo-cell.com

Source: Cryo-Cell International, Inc.